GlassScriptPhysician profile
Kurt M Hesse
NPI 1528026960
$6,537.69
in general payments reported to CMS, 2019-2025
41 companies · $54.40 in 2025
The $54.40 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,085 · 2020: $1,462 · 2021: $2,005 · 2022: $388 · 2023: $382 · 2024: $162 · 2025: $54.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.63 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,112.83 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $650.67 | 2019-2023 | Breztri, Farxiga |
| Amgen INC. | $633.60 | 2019-2023 | |
| Abbvie INC. | $589.48 | 2019-2022 | |
| Lilly USA, LLC | $458.89 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $379.32 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $257.84 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $233.74 | 2019-2022 | |
| Amarin Pharma, INC. | $211.64 | 2019-2021 | |
| Daiichi Sankyo INC. | $203.24 | 2019-2022 | |
| Radius Health, INC. | $156.27 | 2019-2022 | |
| Allergan, INC. | $147.85 | 2020 | |
| Glaxosmithkline, LLC. | $141.67 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $135.91 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.53 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Hesse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.